Overview

  • Product name
  • Description
    Rabbit polyclonal to IRF1
  • Host species
    Rabbit
  • Specificity
    No cross reactivity with other proteins.
  • Tested applications
    Suitable for: WB, ICC, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human IRF1 aa 169-183 (internal sequence).
    Sequence:

    YMQDLEVEQALTPAL


    Database link: P10914

  • Positive control
    • COLO320, U87, HeLa, Jurkat and MCF-7 cell lysates; Human intestinal cancer tissue.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservatives: 0.025% Thimerosal (merthiolate), 0.025% Sodium azide
    Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Sodium phosphate
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab191032 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.1 - 0.5 µg/ml. Predicted molecular weight: 36 kDa.
ICC Use a concentration of 0.5 - 1 µg/ml.
IHC-P Use a concentration of 0.5 - 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • Function
    Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)) and activates those genes. Acts as a tumor suppressor.
  • Involvement in disease
    Defects in IRF1 are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
  • Sequence similarities
    Belongs to the IRF family.
    Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
  • Post-translational
    modifications
    Sumoylation represses the transcriptional activity and displays enhanced resistance to protein degradation. Inactivates the tumor suppressor activity. Elevated levels in tumor cells. Major site is Lys-275. Sumoylation is enhanced by PIAS3 (By similarity). Desumoylated by SENP1 in tumor cells and appears to compete with ubiquitination on C-terminal sites.
    Ubiquitinated. Appears to compete with sumoylation on C-terminal sites.
  • Cellular localization
    Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Interferon regulatory factor 1 antibody
    • Interferon regulatory factor 1 isoform +I9 antibody
    • Interferon regulatory factor 1 isoform d78 antibody
    • Interferon regulatory factor 1 isoform delta4 antibody
    • Interferon regulatory factor 1 isoform delta7 antibody
    • IRF 1 antibody
    • IRF-1 antibody
    • IRF1 antibody
    • IRF1_HUMAN antibody
    • MAR antibody
    • MAR1 antibody
    see all

Images

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded human intestinal cancer tissue labeling IRF1 with ab191032 at 1 μg/ml.

  • All lanes : Anti-IRF1 antibody (ab191032) at 0.5 µg/ml

    Lane 1 : COLO320 cell lysate
    Lane 2 : U87 cell lysate
    Lane 3 : HeLa cell lysate
    Lane 4 : Jurkat cell lysate
    Lane 5 : MCF-7 cell lysate

    Predicted band size: 36 kDa

References

This product has been referenced in:
  • Koelzer VH  et al. Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. Oncoimmunology 6:e1288330 (2017). Read more (PubMed: 28507795) »

See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab191032.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up